Donate
Call the Lung HelpLine
Ask a Question
The following text field filters the results that follow as you type. Use Tab to access the results.
  1. Home
  2. Research & Reports
  3. About Our Research
  4. Research News
  5. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in cur

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis

Respiratory Medicine | December 1, 2022

This study found that a triple therapy of inhaled drugs was the most effective in COPD patients who quit smoking, compared to patients who currently smoked, which is potentially due to relative corticosteroid resistance in people who currently smoke. This is important because while the treatment helped regardless of smoking status, the effect is greater in those who quit. This was a from the ACRC IMPACT study, which explored this new once-daily inhaler treatment combining three drugs.
Fight For Air Climb - Columbus, OH
Columbus, OH | Feb 22, 2025 Fight For Air Climb - Cleveland, OH
Cleveland, OH | Mar 02, 2025
See All Events